Close Menu

NEW YORK (360Dx) – A test that measures remnant lipoproteins and other cardiovascular disease prediction markers has been retrieved from bankruptcy and relaunched by VAP Diagnostics.

VAP Diagnostics has acquired the rights to a technology that provides the basis of the test that clinicians use to assess cardiovascular disease risk. It has also taken on the debt of the test's previous owner Atherotech Diagnostics Lab, which closed its laboratory in Feb. 2016.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.